Gilead price target raised to $116 from $109 at BofA
BofA raised the firm’s price target on Gilead (GILD) to $116 from $109 and keeps a Buy rating on the shares. Q4 results “handily beat ...
Gilead upgraded to Buy from Hold at DZ Bank
DZ Bank upgraded Gilead (GILD) to Buy from Hold with a $108 price target Maximize Your Portfolio with Data Driven Insights:Leverage the power ...
Why Gilead (GILD) Is Advancing Today
Drug maker Gilead (GILD) is rallying 7.5% after the company reported stronger-than-expected fourth-quarter results and ...
Zacks.com on MSN1d
GILD Stock Up on Q4 Earnings and Sales Beat & Upbeat '25 Guidance
Gilead Sciences, Inc. GILD reported better-than-expected fourth-quarter results and provided an upbeat guidance for 2025.
Gilead Sciences Inc (GILD) Q4 2024 Earnings Call Highlights: Strong Growth in HIV and Oncology ...
Gilead Sciences Inc (GILD) reports robust sales growth, driven by HIV and oncology advancements, despite challenges from ...
Nasdaq Gains 1% As Nvidia, Broadcom Surge: Investor Sentiment Improves, Fear & Greed Index Moves To 'Neutral' Zone
The CNN Fear and Greed Index improved to Neutral zone on Monday with the overall market sentiment improving. U.S. stocks closed higher, led by tech gains.
Zacks.com on MSN5d
Gilead Sciences to Report Q4 Earnings: Is a Beat in the Cards?
Biotech giant Gilead Sciences, Inc. GILD is scheduled to report fourth-quarter and full-year 2024 results on Feb. 11, after ...